Core Viewpoint - On March 13, China Eastern Airlines announced plans for share buybacks, while ten A-share listed companies disclosed plans for share reductions, indicating a mixed sentiment in the market regarding stock ownership [1][3]. Group 1: Share Buyback - China Eastern Airlines disclosed intentions to increase its shareholding [1][3]. Group 2: Share Reduction - Huaxiao Precision plans to reduce shares by no more than 0.03% by its directors and executives [5]. - Nanda Optoelectronics' shareholder Shen Jie intends to reduce shares by no more than 1% [5]. - Daotong Technology's director Yin Hui plans to reduce shares by no more than 0.0082% [5]. - Suobao Protein's shareholder Shanghai Bangji intends to reduce shares by no more than 0.75% [5]. - Chenxin Pharmaceutical's shareholder Jiangsu Chenxing plans to reduce shares by no more than 1% [5]. - Daqian Ecology's shareholder Xinhua Publishing Group intends to reduce shares by no more than 3% [5]. - Hongbai New Materials' deputy general manager Li Mingzai plans to reduce shares by no more than 0.02% [5]. - Guo New Energy's shareholder Hongzhan Real Estate intends to reduce shares by no more than 2.07% [5]. - Tengyuan Cobalt's shareholder Changjiang Chendao plans to reduce shares by no more than 2% [5]. - Shentong Technology's shareholder Biheng Investment intends to reduce shares by no more than 3% [5].

证券代码：603367 证券简称：辰欣药业 公告编号：2026-005 辰欣药业股份有限公司股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，辰欣药业股份有限公司（以下简称"公司"或 "辰欣药业"）股东江苏辰昕同泰企业管理有限公司（以下简称"江苏辰昕"） 持有辰欣药业无限售流通股份 1,368,286 股，占辰欣药业总股本的 0.302%。 江苏辰昕系自公司控股股东辰欣科技集团有限公司（以下简称"辰欣科技 集团"）分立而来，所持上述股份来源于辰欣科技集团分立所分配股份。具 体详见公司在上海证券交易所官网披露的《辰欣药业股份有限公司关于控 股股东签订＜分立协议＞暨权益变动的提示性公告》（公告编号：2022-063）、 《辰欣药业股份有限公司关于控股股东存续分立实施完成的公告》（公告编 号：2023-004）等相关公告。 减持计划的主要内容 江苏辰昕拟在减持计划披露之日起 15 个交易日后的 3 个月内，通过集 中竞价交易方式或大宗交易方式减持本 ...

Regulatory Situation - In January 2026, the company was fined a total of 3.125 million yuan by the Shandong Provincial Drug Administration for producing and selling substandard sodium bicarbonate injection, following a penalty decision made in November 2025 [2] Performance and Operating Conditions - For the first three quarters of 2025, the company reported revenue of 2.584 billion yuan, a year-on-year decrease of 13.94%, and a net profit attributable to shareholders of 382 million yuan, down 4.05% year-on-year. In the third quarter alone, net profit increased by 19.61% year-on-year, although the non-recurring net profit declined, indicating fluctuations in profit quality. The company's debt ratio stands at 18.72%, with a gross margin of 55.08% [3] Product Development Progress - The company has multiple innovative drug pipelines in clinical phase II, including WX-081 tablets and WX390 tablets. Additionally, a flu treatment drug, WXSH0208 tablets, has received approval for clinical trials. The subsidiary, Chenshin Fudu Pharmaceutical, has expanded its coverage for oral liquid products under medical insurance, although specific launch dates have not been announced [4] Capital Movements - As of February 6, 2026, the company experienced a weekly net inflow of 12.4296 million yuan in principal funds, with significant daily fluctuations. On February 6, the net inflow reached 20.6828 million yuan. The stock price has been fluctuating around the 17-18 yuan range, with technical indicators showing dispersed holdings and market sentiment influenced by the overall industry [5] Future Development - The company's subsidiary, Shandong Chenshin Fudu Pharmaceutical, has plans to list on the Beijing Stock Exchange, which were approved in 2024, but further progress will depend on official announcements. The pharmaceutical sector is affected by centralized procurement policies and trends in innovative drug development, requiring the company to balance regulatory risks with growth opportunities [6]

Core Viewpoint - The announcement details the change of the sponsor representative for the ongoing supervision of the initial public offering (IPO) of Chenxin Pharmaceutical Co., Ltd. by Zhongtai Securities Co., Ltd. [1] Group 1: Change of Sponsor Representative - Zhongtai Securities has appointed Suo Jianpeng as the new sponsor representative to replace Zeng Liping, who has been reassigned to other responsibilities [1] - The ongoing supervision will continue until the obligations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange are fulfilled [1] Group 2: Acknowledgment of Contributions - The board of directors expresses gratitude for Zeng Liping's contributions during her tenure as the sponsor representative [2] Group 3: Background of New Representative - Suo Jianpeng is the Vice President of the Investment Banking Business Committee at Zhongtai Securities and has previously participated in various IPO projects [3]

Group 1 - The core point of the article is that Chenxin Pharmaceutical announced a change in its sponsor representatives, with Wang Fei and Suo Jianpeng appointed as the new continuous supervision representatives [2] - The continuous supervision period will last until the obligations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange are fulfilled [2]

证券代码：603367 证券简称：辰欣药业 公告编号：2026-004 辰欣药业股份有限公司 关于变更保荐代表人的公告 特此公告。 辰欣药业股份有限公司 董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辰欣药业股份有限公司（以下简称"辰欣药业"或"公司"）于 2026 年 2 月 10 日收到中泰证券股份有限公司（以下简称"中泰证券"）出具的《关于变更辰 欣药业股份有限公司首次公开发行股票并在主板上市项目持续督导保荐代表人的 报告》，具体情况如下： 中泰证券作为公司首次公开发行股票并在上海证券交易所主板上市项目的保 荐机构，原委派王飞先生和曾丽萍女士担任公司持续督导期的保荐代表人。现因 保荐代表人曾丽萍女士工作职责调整，不再担任辰欣药业的持续督导保荐代表人。 为保证公司持续督导工作的正常进行，根据《证券发行上市保荐业务管理办 法》等法规的规定，中泰证券决定委派索剑鹏先生（简历详见附件）接替原保荐 代表人曾丽萍女士担任本项目持续督导的保荐代表人，继续履行对本项目持续督 导的相关职责和义务。 本次保荐代表人变更后，公司持续 ...

Group 1 - China Resources Double Crane and Limin Pharmaceutical were fined 1 million and 3 million yuan respectively for producing sodium bicarbonate injection that failed to meet key quality indicators, specifically "visible foreign matter" and "pH value" [1][5] - The penalties were based on violations of Article 98 of the Drug Administration Law, which outlines strict regulations for drug production [1] - The specific batches involved were identified as 24120602 for China Resources Double Crane and K24110334 for Limin Pharmaceutical, with a total of 23,000 and 30,464 units respectively being deemed non-compliant [3][5] Group 2 - The fines imposed on Limin Pharmaceutical included the confiscation of all non-compliant products and a recovery of illegal gains amounting to 197.5 yuan [3] - For China Resources Double Crane, the total penalty reached 3.0317 million yuan, including the confiscation of illegal gains of 93,300 yuan, bringing the total to 3.125 million yuan [6] - Both companies were penalized following a notice from the National Medical Products Administration regarding 28 batches of non-compliant drugs, highlighting the regulatory scrutiny in the pharmaceutical industry [6]

Group 1 - The core viewpoint of the article is that Chenxin Pharmaceutical (603367.SH) has not exported to EU countries in the past two years while continuing to establish market connections with domestic and international clients [1] Group 2 - The company is actively building market relationships with both domestic and international customers [1] - There has been no export activity to EU countries in the last two years [1]

Core Viewpoint - The Shandong Provincial Drug Administration has imposed an administrative penalty on Chanshin Pharmaceutical Co., Ltd. for producing and selling sodium bicarbonate injection that does not meet national drug standards, resulting in a total fine of 3,125,018.20 yuan [1] Group 1: Regulatory Actions - Chanshin Pharmaceutical was fined 3,031,700 yuan and had 30,464 bottles of the non-compliant sodium bicarbonate injection confiscated due to violations of the Drug Administration Law [1] - The company was found to have produced a batch of sodium bicarbonate injection that failed to meet the required standards, specifically regarding visible foreign substances, and was included in a list of 28 batches of non-compliant drugs [1] Group 2: Company Overview - Chanshin Pharmaceutical, established in 1970 and listed on the Shanghai Stock Exchange in September 2017, is a large comprehensive pharmaceutical company located in Jining, Shandong Province [3] - The company operates five industrial parks covering nearly 2,000 acres, employs over 3,000 people, including more than 1,000 technical professionals, and has total assets of 7.5 billion yuan [3] - Chanshin Pharmaceutical offers over 400 specifications of various drug forms, including large-volume injections, small-volume injections, and raw materials, with a sales network spanning across China and over 50 countries and regions [3]

Group 1 - The company, Chenxin Pharmaceutical Co., Ltd., announced that shareholder Han Yanzhen holds 21,269,329 shares, representing 4.698% of the total share capital [2] - Han Yanzhen has released a pledge on 11,340,000 shares, which accounts for 53.32% of his total holdings and 2.50% of the company's total share capital [2] - After the release of the pledge, Han Yanzhen has no remaining pledged shares [2] Group 2 - As of the announcement date, Han Yanzhen and his concerted action party, Jiangsu Chenxin Tongtai Enterprise Management Co., Ltd., have a cumulative pledge of 0 shares, indicating no harm to the company's interests through non-operating fund occupation, illegal guarantees, or related transactions [3] - There are no subsequent pledge plans following the release of shares, and the company will fulfill its information disclosure obligations if future pledges occur [3] Group 3 - The company has received documentation related to the pledge release, including a fund reconciliation statement and a partial pledge release authorization letter from Han Yanzhen [4]